Biohaven CEO Vlad Coric

Months in­to boom­ing acute mi­graine launch, Bio­haven chas­es pre­ven­tion with oral CGRP med Nurtec ODT

In the sud­den­ly bustling mar­ket for CGRP acute mi­graine fight­ers, Bio­haven has tout­ed its Nurtec ODT as an ob­vi­ous choice for pa­tients with its fast …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.